Potassium propyl 4-oxidobenzoate | 84930-16-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Potassium propyl 4-oxidobenzoate
• 英文别名: potassium;4-propoxycarbonylphenolate
• CAS: 84930-16-5
• 化学式: C10H11KO3
• 分子量: 218.29
• InChiKey: TUMYXYVXTFDMTJ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.67
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2909500000

文献信息

• [EN] GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING GLUCOCORTICOID RECEPTOR ACTIVITY<br/>[FR] PEPTIDES DE LA SUPERFAMILLE DU GLUCAGON PRÉSENTANT UNE ACTION SUR LES RÉCEPTEURS AUX GLUCOCORTICOÏDES
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2013074910A1

  公开（公告）日：2013-05-23

  Provided herein are glucagon superfamily peptides conjugated with GR ligands that are capable of acting at a glucocorticoid receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.

  本文提供了与GR配体结合的葡萄糖素超家族肽，这些肽能够作用于糖皮质激素受体。本文还提供了该发明的结合物的药物组合物和工具包。此外，本文还提供了治疗疾病的方法，例如代谢紊乱，如糖尿病和肥胖，包括给予该发明的结合物。
• [EN] DESMETHYLANETHOLE TRITHIONE DERIVATIVES FOR THE TREATMENT OF DISEASES LINKED TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES (ROS) PRODUCTION<br/>[FR] DÉRIVÉS DESMÉTHYLANETHOLE TRITHIONE POUR LE TRAITEMENT DE MALADIES LIÉES À LA PRODUCTION DE FORMES RÉACTIVES DE L'OXYGÈNE (FRO) D'ORIGINE MITOCHONDRIALE
  申请人：OP2 DRUGS

  公开号：WO2018162581A1

  公开（公告）日：2018-09-13

  The present invention relates to desmethylanethole trithione ( AOX ) and derivatives thereof, especially derivatives of formula (I), for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.

  本发明涉及去甲甲醚三硫醚（AOX）及其衍生物，特别是式（I）的衍生物，用于预防和治疗由线粒体产生和影响的活性氧物质（ROS）引起的疾病的启动和/或进展。
• Dermatological compositions and methods
  申请人：——

  公开号：US20030017181A1

  公开（公告）日：2003-01-23

  Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.

  包含一个或多个麻醉剂和/或一个或多个抗炎剂和/或氨、钠和钾盐的组合的皮肤科配方（制备和使用方法），最好是α-羟基酸的盐。
• [EN] SUBSTITUTED CYCLODEXTRIN-METAL COMPLEXES AND USES THEREOF<br/>[FR] COMPLEXES DE CYCLODEXTRINE SUBSTITUÉE-MÉTAL ET LEURS UTILISATIONS
  申请人：BIOCYDEX

  公开号：WO2019215285A1

  公开（公告）日：2019-11-14

  The present invention relates to a complex of Ag, Zn, Cu, Pt, Au, oxides, hydroxides and salts thereof; with a cyclodextrin of formula (I) as defined in claim 1. Advantageously, the complex further comprises an organic therapeutic agent, preferably an antibiotic agent. The complexation according to the invention advantageously maintains the metal: organic therapeutic agent molar ratio. Even more advantageously, the complexation according to the invention enhances the intrinsic aqueous solubility of the metal-organic therapeutic agent association. The present invention further relates to compositions, pharmaceutical compositions and adequate formulations and uses thereof as well as devices comprising a complex of the invention. Lastly, the invention relates to a method for improving the aqueous solubility of a metal selected from Ag, Zn, Cu, Pt, Au, Ru, As, Sb, Bi, Ti, V, Ni, Hg, Pb, Co, oxides, hydroxides and salts thereof by providing a reaction mixture comprising said metal, an aqueous medium and a cyclodextrin of formula (I) as defined in claim 1.

  本发明涉及一种Ag、Zn、Cu、Pt、Au、氧化物、氢氧化物和盐的复合物；其中包括公式（I）所定义的环糊精。优选地，该复合物还包括有机治疗剂，特别是抗生素剂。本发明的复合作用有利于维持金属：有机治疗剂的摩尔比。更具优势的是，本发明的复合作用增强了金属-有机治疗剂的固有水溶性。本发明还涉及该复合物的组合物、制药组合物和适当的配方及其用途，以及包括该复合物的器件。最后，本发明涉及一种通过提供包括所述金属、水介质和公式（I）所定义的环糊精的反应混合物来改善Ag、Zn、Cu、Pt、Au、Ru、As、Sb、Bi、Ti、V、Ni、Hg、Pb、Co、氧化物、氢氧化物和盐等金属的水溶性的方法。
• Glucagon/glp-1 receptor co-agonists
  申请人：Indiana University Research and Technology Corporation

  公开号：EP2676673A2

  公开（公告）日：2013-12-25

  Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming intramolecular bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, acylation, alkylation, substitution of carboxy terminal amino acids, C-terminal truncation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).

  已公开的修饰胰高血糖素肽在胰高血糖素受体上的效力比原生胰高血糖素更强。通过形成分子内桥或用酰胺基团取代末端羧酸来进一步修饰胰高血糖素肽，可产生具有胰高血糖素/GLP-1 受体共激动剂活性的肽。这些高活性胰高血糖素类似物的溶解性和稳定性可通过对多肽进行聚乙二醇化、酰化、烷基化、羧基末端氨基酸的取代、C-末端截断或添加选自 SEQ ID NO: 26 (GPSSGAPPPS)、SEQ ID NO: 27 (KRNRNNIA) 和 SEQ ID NO: 28 (KRNR)的羧基末端肽来进一步改善。